These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 23164420)

  • 21. Panniculitis and lipoatrophy after subcutaneous injection of interferon beta-1b in a patient with multiple sclerosis.
    O'Sullivan SS; Cronin EM; Sweeney BJ; Bourke JF; Fitzgibbon J
    J Neurol Neurosurg Psychiatry; 2006 Dec; 77(12):1382-3. PubMed ID: 16782776
    [No Abstract]   [Full Text] [Related]  

  • 22. Local reactions associated with subcutaneous injections of both beta-interferon 1a and 1b.
    García-F-Villalta M; Daudén E; Sánchez J; Fraga J; Ramo C; García-Díez A
    Acta Derm Venereol; 2001 May; 81(2):152. PubMed ID: 11501663
    [No Abstract]   [Full Text] [Related]  

  • 23. Embolia cutis medicamentosa following interferon beta injection.
    Koontz D; Alshekhlee A
    Mult Scler; 2007 Nov; 13(9):1203-4. PubMed ID: 17967846
    [No Abstract]   [Full Text] [Related]  

  • 24. Arthritis during interferon beta-1b treatment in multiple sclerosis.
    Altintas A; Alici Y; Melikoğlu M; Siva A
    Mult Scler; 2002 Dec; 8(6):534-6. PubMed ID: 12474998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Interferon beta-1b retinopathy during a treatment for multiple sclerosis].
    Sommer S; Sablon JC; Zaoui M; Rozot P; Hosni A
    J Fr Ophtalmol; 2001 May; 24(5):509-12. PubMed ID: 11397988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Subacute cutaneous lupus erythematosus and interferon beta-1 a].
    Schmutz J; Barbaud A; Tréchot P
    Ann Dermatol Venereol; 2000 Feb; 127(2):237. PubMed ID: 10739993
    [No Abstract]   [Full Text] [Related]  

  • 27. Lethal capillary leak syndrome after a single administration of interferon beta-1b.
    Niederwieser G
    Neurology; 2000 Apr; 54(7):1545-6. PubMed ID: 10751284
    [No Abstract]   [Full Text] [Related]  

  • 28. Interferon-beta treatment in patients with childhood-onset multiple sclerosis.
    Mikaeloff Y; Moreau T; Debouverie M; Pelletier J; Lebrun C; Gout O; Pedespan JM; Van Hulle C; Vermersch P; Ponsot G
    J Pediatr; 2001 Sep; 139(3):443-6. PubMed ID: 11562627
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adverse effects with Avonex.
    Am J Nurs; 2003 Jul; 103(7):64F. PubMed ID: 12877129
    [No Abstract]   [Full Text] [Related]  

  • 30. New drug information.
    JAAPA; 2009 Dec; 22(12):14. PubMed ID: 24887461
    [No Abstract]   [Full Text] [Related]  

  • 31. C1-inhibitor activity and plasma concentrations in patients with monoclonal gammopathies: implications for treatment with recombinant interferon-beta 1b.
    Schmidt S; Schneider T; Schmidt-Wolf I; Ko Y; Schlegel U; Klockgether T; Hertfelder HJ
    Mult Scler; 2004 Apr; 10(2):243-4. PubMed ID: 15124772
    [No Abstract]   [Full Text] [Related]  

  • 32. Drug induced liver injury secondary to interferon-beta (IFN-beta) in multiple sclerosis.
    Byrnes V; Afdhal N; Challies T; Greenstein PE
    Ann Hepatol; 2006; 5(1):56-9. PubMed ID: 16531969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Local pain during REBIF injection is not due to acidic pH.
    Buttmann M; Goebeler M; Rieckmann P
    J Neurol Neurosurg Psychiatry; 2004 Jul; 75(7):1078. PubMed ID: 15201384
    [No Abstract]   [Full Text] [Related]  

  • 34. Calcified subcutaneous nodules: a long-term complication of interferon beta-1a therapy.
    Macbeth AE; Kendall BR; Smith A; Saldanha G; Harman KE
    Br J Dermatol; 2007 Sep; 157(3):624-5. PubMed ID: 17596164
    [No Abstract]   [Full Text] [Related]  

  • 35. The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-la: analysis of data from clinical trial and post-marketing surveillance settings.
    Sandberg-Wollheim M; Kornmann G; Bischof D; Moraga MS; Hennessy B; Alteri E
    Mult Scler; 2011 Apr; 17(4):431-40. PubMed ID: 21486902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Panniculitis after subcutaneous injection of interferon beta in a multiple sclerosis patient.
    Heinzerling L; Dummer R; Burg G; Schmid-Grendelmeier P
    Eur J Dermatol; 2002; 12(2):194-7. PubMed ID: 11872423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Asymptomatic peripheral retinal hemorrhages as a manifestation of interferon beta 1a retinopathy.
    Bakri SJ; Swanson JW
    Semin Ophthalmol; 2015 Jan; 30(1):56-7. PubMed ID: 23952180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Life-threatening acute pancreatitis associated with interferon beta-1a treatment in multiple sclerosis.
    Midgard R; Ertresvåg K; Trondsen E; Spigset O
    Neurology; 2005 Jul; 65(1):170-1. PubMed ID: 16009917
    [No Abstract]   [Full Text] [Related]  

  • 39. Chronic myeloid leukaemia in two multiple sclerosis patients on interferon beta-1a.
    Almeida L; Neves M; Cardoso E; Melo A
    J Clin Pharm Ther; 2009 Feb; 34(1):125-7. PubMed ID: 19125911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic lupus erythematosus induced by interferon β1 therapy in a patient with multiple sclerosis.
    Bahri DM; Khiari H; Essouri A; Laadhar L; Zaraa I; Mrabet A; Meddeb N; Sellami S
    Fundam Clin Pharmacol; 2012 Apr; 26(2):210-1. PubMed ID: 21323997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.